Uncategorized
FDA Reviews Chantix Cardiovascular Risk
The FDA is informing the public about the results of a meta-analysis that compared patients who received Chantix (varenicline; Pfizer) to patients who received placebo.
Your search for smoking cessation returned 5 results
Uncategorized
SAFETY ALERT: Chantix May Raise Cardiovascular Risk
The FDA has notified the public that the smoking cessation aid Chantix (varenicline; Pfizer) may be associated with a small, increased risk of certain cardiovascular events in patients with cardiovascular disease.
Uncategorized
Additional warnings for Chantix
The labeling for Chantix (varenicline tartrate, from Pfizer) has been updated with a warning to observe patients for serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior.
Uncategorized
Additional warnings for varenicline and bupropion
The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.
Uncategorized
FDA Issues New Warnings for Chantix
The Food and Drug Administration (FDA) has announced that the labeling for varenicline (Chantix; Pfizer) has been updated to include information on changes to alcohol tolerance and risk of seizures associated with use of the drug.
